Cases & Deals

Jefferies International and Kempen complete DKK 998 million share placing by Genmab

Clients Jefferies International Limited and Kempen & Co N.V.

Jones Day advised Jefferies International Limited and Kempen & Co N.V. in connection with the sale of shares in an accelerated book build placing by Genmab A/S, a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. A total of 4,600,000 shares, equivalent to approximately 9% of the shares in Genmab, were sold at a price of DKK 217 per share, raising total gross proceeds of DKK 998 million (US$182.7 million) for Genmab.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.